Sar113244 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
49 | Systemic lupus erythematosus | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02331810 (ClinicalTrials.gov) | April 2016 | 5/12/2014 | Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients | A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patient | Systemic Lupus Erythematosus | Drug: SAR113244;Drug: placebo | Sanofi | NULL | Withdrawn | 18 Years | 75 Years | Both | 0 | Phase 1 | NULL |
2 | NCT02321709 (ClinicalTrials.gov) | November 2014 | 5/12/2014 | Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients | A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patients | Systemic Lupus Erythematosus | Drug: SAR113244;Drug: placebo | Sanofi | NULL | Completed | 18 Years | 75 Years | Both | 21 | Phase 1 | Germany |